drugset
drugset / Trial / NCT06238687

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

NCT06238687 ↗

Phase 1/2 Completed 19 enrolled Tasly Pharmaceutical Group Co., Ltd Sutro Biopharma, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity, and preliminary efficacy of STRO-002 in patients with advanced malignant solid tumors.

Timeline

Start
2023-11-08
Primary completion
2025-06-06
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Luveltamab tazevibulin Monoclonal antibody 3.5 mg/kg Intravenous
Subject Luveltamab tazevibulin Monoclonal antibody 4.3 mg/kg Intravenous
Subject Luveltamab tazevibulin Monoclonal antibody 5.2 mg/kg Intravenous

Indications

cancer